Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered food app and smart glucose monitor could transform diabetes management

NCT ID NCT07533604

Disease control Sponsor: Ramathibodi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether an AI app called SnapD, which recognizes Thai food and estimates nutrition, can help people with type 2 diabetes and overweight improve their blood sugar control. Some participants will also use a continuous glucose monitor (CGM) that tracks sugar levels in real time. Over 8 weeks, 45 adults will be randomly assigned to use the app with or without the CGM, or receive standard diabetes education alone. The goal is to see if these digital tools lead to better HbA1c levels and healthier habits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SnapD (AI-powered food analysis app) and Linx CGM (continuous glucose monitor)
What this could lead to
If successful, this could provide a practical, culturally tailored digital tool to help people with type 2 diabetes better manage their blood sugar and weight.
What could go wrong
This is a small pilot study with only 45 participants over 8 weeks, so results may not apply broadly. The app is new and untested, and participants must keep their diabetes medications unchanged, which limits real-world flexibility.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 65 years, male or female at birth 2. Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²) 3. Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date 4. Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration 5. Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application 6. Able and willing to adhere intervention, including using snapD and CGM Exclusion Criteria: 1. Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period 2. Current participation in another interventional clinical trial 3. Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists) 4. Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device 5. known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Medicine, Ramathibodi Hospital,

    RECRUITING

    Bangkok, Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.